XML 44 R33.htm IDEA: XBRL DOCUMENT
v3.25.3

FAIR VALUE MEASUREMENTS (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Fair Value Disclosures [Abstract] |
Schedule of fair value measurements along with the level within the fair value hierarchy in which the fair value measurements fall | The following table presents the Company’s fair value measurements as of September 30, 2025 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands) |  | Fair Value at September 30, 2025 |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Cash, cash equivalents, and restricted cash |  |  |  |  |  |  |  |
Cash and money market |  | $ | 781,729 |  |  | $ | 781,729 |  |  | $ | — |  |  | $ | — |
U.S. government agency securities |  | 7,308 |  |  | — |  |  | 7,308 |  |  | — |
Marketable securities |  |  |  |  |  |  |  |
Corporate bonds |  | $ | 104,255 |  |  | $ | — |  |  | $ | 104,255 |  |  | $ | — |
U.S. government agency securities |  | 69,085 |  |  | — |  |  | 69,085 |  |  | — |
Asset backed securities |  | 29,366 |  |  | — |  |  | 29,366 |  |  | — |
Equity securities |  | 11,352 |  |  | 11,352 |  |  | — |  |  | — |
Non-marketable securities |  | $ | 53,262 |  |  | $ | — |  |  | $ | — |  |  | $ | 53,262 |
Liabilities |  |  |  |  |  |  |  |
Contingent consideration |  | $ | (284,113) |  |  | $ | — |  |  | $ | — |  |  | $ | (284,113) |
Total |  | $ | 772,244 |  |  | $ | 793,081 |  |  | $ | 210,014 |  |  | $ | (230,851) |
The following table presents the Company’s fair value measurements as of December 31, 2024 along with the level within the fair value hierarchy in which the fair value measurements, in their entirety, fall.
(In thousands) |  | Fair Value at December 31, 2024 |  | Quoted Prices in Active Markets for Identical Assets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
Cash, cash equivalents and restricted cash |  |  |  |  |  |  |  |
Cash and money market |  | $ | 595,548 |  |  | $ | 595,548 |  |  | $ | — |  |  | $ | — |
Restricted cash (1) |  | 5,747 |  |  | 5,747 |  |  | — |  |  | — |
U.S. government agency securities |  | 5,341 |  |  | — |  |  | 5,341 |  |  | — |
Marketable securities |  |  |  |  |  |  |  |
Corporate bonds |  | $ | 206,874 |  |  | $ | — |  |  | $ | 206,874 |  |  | $ | — |
U.S. government agency securities |  | 140,952 |  |  | — |  |  | 140,952 |  |  | — |
Asset backed securities |  | 83,339 |  |  | — |  |  | 83,339 |  |  | — |
Equity securities |  | 5,972 |  |  | 5,972 |  |  | — |  |  | — |
Non-marketable securities |  | $ | 796 |  |  | $ | — |  |  | $ | — |  |  | $ | 796 |
Liabilities |  |  |  |  |  |  |  |
Contingent consideration |  | $ | (282,212) |  |  | $ | — |  |  | $ | — |  |  | $ | (282,212) |
Total |  | $ | 762,357 |  |  | $ | 607,267 |  |  | $ | 436,506 |  |  | $ | (281,416) |
_________________________________ (1)Restricted cash primarily represents cash held by a third-party financial institution as part of a cash collateral agreement related to the Company’s credit card program. The restrictions will lapse upon the termination of the agreements or the removal of the cash collateral requirement by the third-parties.
Fair Value, by Balance Sheet Grouping [Table Text Block] | The following table summarizes the Company’s non-marketable investments, which are primarily included in other long-term assets on the condensed consolidated balance sheet as of September 30, 2025 and December 31, 2024:
(In thousands) |  | September 30, 2025 |  | December 31, 2024
Investments for which the fair value option has been elected |  | $ | 53,262 |  |  | $ | 796 |
Investments without readily determinable fair values |  | 50,941 |  |  | 50,448 |
Equity method investments |  | 7,383 |  |  | 7,488 |
Total |  | $ | 111,586 |  |  | $ | 58,732 |
Securities Owned Not Readily Marketable [Table Text Block] | Gains and losses recorded on non-marketable securities for which the fair value option has been elected are recognized in investment income, net in the condensed consolidated statement of operations. The following table provides a reconciliation of the beginning and ending balances of non-marketable securities valued using the fair value option:
(In thousands) |  | Non-Marketable Securities
Beginning balance, January 1, 2025 |  | $ | 796 |
Purchases of non-marketable securities |  | 50,850 |
Changes in fair value |  | 1,616 |
Settlement of non-marketable securities |  | — |
Ending balance, September 30, 2025 |  | $ | 53,262 |
Other Investments Not Readily Marketable | Investments without readily determinable fair values had the following cumulative upward and downward adjustments and aggregate carrying amounts:
(In thousands) |  | September 30, 2025 |  | September 30, 2024
Cumulative upward adjustments (1) |  | $ | 5,595 |  |  | $ | 5,102 |
Cumulative downward adjustments and impairments (2) |  | (16,850) |  |  | (15,071) |
Aggregate carrying value |  | 50,941 |  |  | 52,227 |
_________________________________ (1) There were no material upward adjustments recorded for the three and nine months ended September 30, 2025 and 2024. (2) There were no material downward adjustments or impairments recorded for the three and nine months ended September 30, 2025 and 2024.
Schedule of fair value of contingent consideration | The following table provides a reconciliation of the beginning and ending balances of contingent consideration:
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
(In thousands) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Beginning balance |  | $ | 275,408 |  |  | $ | 277,921 |  |  | $ | 282,212 |  |  | $ | 288,657 |
Changes in fair value (1) |  | 8,705 |  |  | 5,310 |  |  | 21,901 |  |  | (2,326) |
Payments (2) |  | — |  |  | — |  |  | (20,000) |  |  | (3,100) |
Ending balance |  | $ | 284,113 |  |  | $ | 283,231 |  |  | $ | 284,113 |  |  | $ | 283,231 |
______________ (1)The change in fair value of the contingent consideration liability is included in general and administrative expenses in the condensed consolidated statement of operations for the three and nine months ended September 30, 2025 and 2024. (2)Payments were made in the nine months ended September 30, 2025 and 2024 to settle the product development milestone contingent consideration liabilities previously recorded related to the Company’s acquisitions of Ashion Analytics, LLC (“Ashion”) and OmicEra Diagnostics GmbH, respectively.

X
- Definition Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details
Name: | us-gaap_FairValueByBalanceSheetGroupingTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments. + References No definition available. + Details
Name: | us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details
Name: | us-gaap_ScheduleOfOtherInvestmentsNotReadilyMarketableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of not readily marketable securities and investments including, but not limited to, description of security or investment, fair value and value as measured by quoted price. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details
Name: | us-gaap_ScheduleOfSecuritiesOwnedNotReadilyMarketableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration